Tolebrutinib belongs to the class of Bruton tyrosine kinase inhibitors. Recently, negative news weakened hope for the BTKi, particularly among people with progressive multiple sclerosis. Professor Mathias Mäurer summarizes new information on Tolebrutinib in the
Continue reading
Women of childbearing age are, compared to men, underrepresented in MS therapy. This was shown by a recent study. There is a gender gap in the use of immunomodulatory therapies (DMT). However, this does not
Continue reading
There has been a lot of progress in the development of MS therapy, since the first interferon for multiple sclerosis came on the market in the mid-90s. There are now almost 20 immunomodulatory agents approved.
Continue reading
So far, multiple sclerosis has been divided into 5 subtypes. Researchers are increasingly moving away from this model. Instead, MS appears to be a single entity, a dynamic process. Does this mean we can now
Continue reading
In this second video of the three-part series “Cortisone in MS”, Prof. Mathias Mäurer explains what possible side effects cortisone can have in MS, what can be done against it and why the question of
Continue reading
In this video of the three-part series “Corticosteroids in MS,” Prof. Mathias Mäurer explains what corticosteroids are, how they are used in multiple sclerosis, when corticosteroids are used in MS, what effect they have on
Continue reading
We roughly distinguish two different classes of MS drugs. On the one hand, the so-called basic therapies, which can be given in cases of mild/moderate MS, and on the other hand, the highly effective therapies
Continue readingI don’t want to come across as a know-it-all at this point. But after my remarks on the Mollii Suit have caused excitement, I would like to briefly address the most recent court rulings on
Continue reading
Where does conventional medicine end, where do alternative healing methods begin? This article and video deal with evidence-based medicine, alternative methods and the role of the psyche in the development of MS. Prof. Mathias Mäurer
Continue reading
The Epstein-Barr virus (EBV) persists for life in the human body after a primary infection. Most often, the infection has no consequences, but the virus can also cause severe illness and is associated with the
Continue reading
Unsere Website verwendet Cookies und sammelt dabei Informationen über Ihren Besuch, um unsere Website zu verbessern (durch Analyse), Ihnen Social Media-Inhalte und relevante Werbung anzuzeigen. Weitere Informationen finden Sie auf unserer Seite . Sie können zustimmen, indem Sie auf die Schaltfläche "Akzeptieren" klicken.
Cookie-Einstellungen
Unten können Sie auswählen, welche Art von Cookies Sie auf dieser Website zulassen. Klicken Sie auf die Schaltfläche "Cookie-Einstellungen speichern", um Ihre Auswahl zu übernehmen.
Dieser Inhalt ist gesperrt. Akzeptieren Sie Cookies in der Kategorie '%CC%', um diesen Inhalt anzuzeigen.
